title: Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer.
abstract: Breast cancer frequently metastasizes to the skeleton resulting in bone degradation due to osteoclast activation. Metastases also downregulate differentiation and the bone-rebuilding function of osteoblasts. Moreover, cancer cells trigger osteoblast inflammatory stress responses. Pro-inflammatory mediators such as interleukin (IL)-6, monocyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), expressed by osteoblasts (MC3T3-E1) stimulated with human breast cancer cell (MDA-MB-231) conditioned medium, are pivotal to osteoclast activation and metastasis. Given that these genes are regulated by nuclear factor-kappaB (NF-kappaB), a redox-sensitive transcription factor, we hypothesized that selenium (Se) could abrogate the inflammatory response to metastatic breast cancer cells by modulating NF-kappaB. Caffeic acid phenethyl ester and parthenolide inhibited NF-kappaB activation, as seen by gel shift assays and immunoblotting for p65 in nuclear fractions, as well as decreased production of IL-6 and MCP-1. Supplementation of MC3T3-E1 with methylseleninic acid (MSA) (0.5 microM to 4 microM) reduced the activation of NF-kappaB leading to a decrease in IL-6, MCP-1, COX-2 and iNOS in response to MDA-MB-231 conditioned medium. Addition of MSA to osteoblasts for as little as 15 min suppressed activation of NF-kappaB suggesting that short-lived active metabolites might be involved. However, brief exposure to MSA also brought about an increase in selenoprotein glutathione peroxidase 1. In summary, our data indicate that the osteoblast response to metastatic breast cancer cells is regulated by NF-kappaB activation, which can be effectively suppressed by MSA either through short-lived active metabolites and/or selenoproteins. Thus, Se supplementation may prevent the osteoblast inflammatory response or dampen the vicious cycle established when breast cancer cells, osteoblasts and osteoclasts interact.
authors.affiliation: Department of Biochemistry and Molecular Biology, 431 South Frear Building, Penn State University, University Park, PA 16802, USA.
authors.forename: Yu-Chi
authors.initials: YC
authors.lastname: Chen
authors.forename: Donna M
authors.initials: DM
authors.lastname: Sosnoski
authors.forename: Ujjawal H
authors.initials: UH
authors.lastname: Gandhi
authors.forename: Leah J
authors.initials: LJ
authors.lastname: Novinger
authors.forename: K Sandeep
authors.initials: KS
authors.lastname: Prabhu
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Mastro
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000378:metabolism / Q000517:prevention & control / Q000556:secondary; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002450:Cell Communication / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D018932:Chemokine CCL2 / Q000096:biosynthesis; D017077:Culture Media, Conditioned / Q000494:pharmacology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D005260:Female; D006801:Humans; D007249:Inflammation; D015850:Interleukin-6 / Q000096:biosynthesis; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis; D016566:Organoselenium Compounds / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D012643:Selenium / Q000378:metabolism*
chemical_list: D018932:Chemokine CCL2; D017077:Culture Media, Conditioned; D015850:Interleukin-6; D016328:NF-kappa B; D016566:Organoselenium Compounds; C008493:methylselenic acid; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; D012643:Selenium